$1866 | SAVE $329 | Single User
$6566 | SAVE $1,159 | Site License
$12708 | SAVE $2,242 | Global License

Innovations in Drug Pricing and Reimbursement (2016)
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 01 Feb 2016 | 303 | In Stock
Related Topics: Biosimilars , Pharmacy

Introduction

Introduction


Is the drug pricing bubble about to burst?


Drug costs are becoming unaffordable and draconian cost containment strategies

are being employed.


The pharma industry is winning few friends when it comes to drug pricing.

Public, health professional, political and payer hostility is growing worldwide as the

prices of new drugs for chronic disease, specialty medicines and even generics grow

excessively. How are payers in the US and Europe responding and what cost containment

strategies are being – and could be – employed to cap rampant and increasingly unaffordable

drug bills?


The pharma industry is winning few friends when it comes to drug pricing.

Public, health professional, political and payer hostility is growing worldwide as the

prices of new drugs for chronic disease, specialty medicines and even generics grow

excessively. How are payers in the US and Europe responding and what cost containment

strategies are being – and could be – employed to cap rampant and increasingly unaffordable

drug bills?


“It's pretty discouraging, unfortunately. It makes you think these companies

are not really involved in healthcare. I don't think they are…They just are profit

centres.” US Payer


Puchase Reasons


Answering key questions:


  • A Fundamental Driver: Why, and to what extent, is the pharma industry’s focus

    on orphan diseases and high-end biologics creating such an issue for payers?


  • The End of the Wild West? Freeing Medicare to negotiate drug pricing and PBMs

    utlilising competitive pressures to lower costs are just some of the solutions to

    controlling US drug prices– what else is on the table and how extreme might regulators get?


  • European Variance: Reference pricing, price-volume agreements, tendering,

    early benefit assessments, HTA cost/benefits assessments, risk-sharing and whole system

    product value are all being employed – but where and with what success?


  • Stakeholder Buy-In: Why, and how, might early and open dialogue between

    industry and payers benefit both parties?


  • Positive Message? Why is industry failing to get its societal and cost-

    benefit message heard, and what more could it do to win support?


  • Same Old, Same Old: In the face of solid profits does industry’s narrative of

    justifying high drug prices to fund innovation and development need an overhaul?


  • Risk Sharing: Are risk-sharing, value-based pricing and pricing by indication

    the best schemes moving forward?


  • Local Market, Local Problems: Each country has gone its own way in controlling

    cost – what could they learn from each other and is drug pricing now a regional rather than

    just a national issue?


  • ...

  • With this report you will be able to:


  • Understand the fundamental research trends that are driving payer concerns and

    disquiet


  • Learn which reimbursement strategies are being employed

  • Assess the multi-country alliances that are forming to negotiate better

    prices


  • Appreciate how cost-containment measures vary from country to country


  • Understand why and how cost containment measures are likely to

    intensify


  • Address the pressing need for companies to explain their pricing policies

    better and support brands with outcomes evidence


  • Know what payers want and formulate better communication strategiesin

    healthcare. I don't think they are…They just are profit centres.” US Payer


  • Key Topics explored


  • Is the pharma industry digging its own grave? Price increases above and

    beyond any economic indicator, price gouging and products which bring little clinical

    advantage but big cost are creating much ill will and leading to wider and more severe cost

    containment policies.


  • Cash strapped payers cannot afford to meet all the demands of aging

    populations – how can industry positively respond to these concerns?


  • Even the hitherto free market of the US is now actively seeking ways to

    control cost. Moves to liberate the negotiating hand of Medicare and a range of other

    control measures will limit the industry’s scope to act. How far could these developments

    go?


  • European countries share the same problems but each has taken a different

    approach – will consensus emerge and what are the key market variables that pharma should

    know about?


  • Drug intervention plays a critical role in controlling disease. Effective

    medicines and good adherence can improve the patient’s quality of life and significantly

    reduce overall health expenditure. But these benefits often go unrecognised. Is there a

    communication issue pharma needs to address?


  • Biosimilars hold the prospect of lower prices for biologics, but will this

    sector ever really gain traction in the market?


  • Expert Contributors


    The report is informed through in-depth interviews with payers responsible for

    drug budgets in the US and EU5 leading economies. To ensure open and critical responses

    all contributors are anonymous but include:


  • Pharmacy director at US-based pharmacy-benefit management organisation


  • Chief pharmacist at NHS Foundation Trust in England

  • Drug-reimbursement manager for German health insurers

  • Head of pharmacy at French university hospital

  • Advisor to Spanish hospitals on pharmacoeconomics and formulary inclusion of

    new medicines


  • Director, department of clinical pharmacy in Italy

  • About FirstWord


    FirstWord is an innovative industry intelligence leader serving over 240,000

    Pharma and MedTech professionals worldwide. FirstWord offers a range of products and

    services designed to help your company gain a competitive edge by making key business

    decisions with speed and confidence.


    FirstWord Pharma PLUS is a personalised and comprehensive intelligence service

    delivering up-to-the-minute pharma news, insight, analysis and expert views of importance

    to your company’s success.


    FirstWord Reports deliver timely, need-to-know intelligence about your products,

    your competitors and your markets. Covering biosimilars, market access, medical affairs,

    sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and

    intelligence on the challenges facing pharma today.

    Table of Contents
    for Innovations in Drug Pricing and Reimbursement (2016) [Published by FirstWord Pharma]

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    303 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    SAVE 15% today! Trends and Innovations in Companion Diagnostics
    IntroductionAre companion diagnostics becoming a “must have” for market access? Companion Diagnostic...
    01 Apr 2016 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Drug Delivery - Innovations, trends, and their impact on pharma
    IntroductionWhy you need Drug Delivery - Innovations, trends, and their impact on pharmaRevolutionar...
    01 Nov 2015 by FirstWord Pharma USD $1,866 (normally
    USD $2,195)
    More Info
    SAVE 15% today! Syncro Medical Innovations - Medical Equipment - Deals and Alliances Profile
    SummarySyncro Medical Innovations (Syncro Medical) is a medical device company that develops feeding...
    23 Oct 2015 by Global Data USD $213 (normally
    USD $251)
    More Info
    SAVE 15% today! Innovations in Medical Communications and Information
    IntroductionToday’s medical information and communications teams must look “outside the box” for cos...
    01 Aug 2015 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Trends and Innovations in Key Account Management
    IntroductionYour customers need and demand more from you today. Key Account Management (KAM) is the ...
    01 Jul 2015 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Trends & Innovations Sales Force Effectiveness
    IntroductionWhat makes an ideal modern pharma sales representative and what skills, knowledge, tools...
    01 Apr 2015 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Trends and Innovations in Patient Adherence
    IntroductionTaking the right dose of the right medicine at the right time is key to improving health...
    01 Mar 2015 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Trends and Innovations in Lifecycle Management
    IntroductionTrends and Innovations in Lifecycle Management (LCM) presents business-critical insights...
    01 Feb 2015 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Trends and Innovations in Drug Pricing
    IntroductionFirstWord’s Trends and Innovations in Drug Pricing report dissects international trends ...
    01 Jan 2015 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Innovations in Multichannel Marketing
    IntroductionFirstWord goes beyond the multichannel marketing hype to explore what multichannel marke...
    01 Aug 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Innovations in Drug Pricing and Reimbursement (2016) [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...